+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain Publishes Pharmaceutical Analytical Testing Outsourcing Market Report 2020-2030

29 July 2020
Pharma

Visiongain has launched a new report Pharmaceutical Analytical Testing Outsourcing Market Report 2020-2030: Forecasts by Service (Bioanalytical, Stability, Method Development & Validation, and Others), Product (Active Pharmaceutical Ingredient (API), Additives, Finished Products), End-user (Biopharmaceuticals and Pharma Companies, Contract Manufacturing Organizations, Others) and by Region (North America, Europe, Asia Pacific, Latin America & MEA), Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

Pharmaceutical analytical testing are a series of clinical trials used to ensure the safety of new manufactured drugs. Before the launch of a new drug in the market, it needs to undergo method development & validation, bioanalytical testing, and stability testing. These tests help to identify and quantify the components in pharmaceutical drugs. The preference to outsource these services has increased owing to the high competition for disease specific drugs and the lengthy drug approval procedures. Biopharmaceuticals and pharmaceutical companies is largest contributor towards the pharmaceutical analytical testing outsourcing market as these services help to reduce costs and improve efficiency.

Quicker and reliable results, improved drug efficiency, price benefits associated with outsourcing these tests, and data safety are some of the key factors increasing the demand for outsourcing pharmaceutical analytical testing. In addition, there is an increase in preference for outsourcing these analytical tests owing to the availability of access to therapeutic expertise, pricing concerns, enhancement in operational efficiency, and benefit from on-demand services. The technological advancement has helped to shorten the lifecycle of drug production leading to rapid development of new products. These factors are expected to increase the demand for outsourcing pharmaceutical analytical testing in the near future.

The increase in demand for analytical drugs, biosimilars, and biopharmaceutical products, rise in number of products in the pipeline, and increase in investment in R&D activities for drug development further drives the growth of global pharmaceutical analytical testing outsourcing market. However, varied outsourcing expenditures by companies and the high cost associated with pharmaceutical testing are expected to hamper the market growth.

The Visiongain report analyst commented “As outsourcing analytical testing helps to reduce the time for drug development and enhances drug safety, pharmaceutical and biopharmaceutical companies are increasing using outsourcing services for drug development process. Moreover, the outsourcing companies help to provide the regulatory bodies with the required analytical details on drugs and help provide the pharmaceutical companies a competitive edge for the production of generic and biosimilar medications.”

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Toxikon, Inc., Intertek Group PLC, SGS SA, Eurofins Scientific, Boston Analytical, Pace Analytical Services, LLC, West Pharmaceutical Services, Inc., WuXi AppTec, Inc., Intertek Group Plc, Pharmaceutical Product Development, LLC, and Charles River Laboratories International, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever